Body Pharm Retatrutide 64 Pen

Body Pharm Retatrutide 64 Pen: Dosing, Price & Storage Guide

The Body Pharm Retatrutide 64 Pen is a prefilled, ready-to-inject subcutaneous pen containing 64mg of retatrutide, retailing at R5,000 on Beskinny (2024–2025) and dosed once weekly using a 4-week titration: 2mg → 4mg → 8mg → 8–12mg maintenance [2]. This pricing reflects the South African compounded peptide market as of early 2026, where retatrutide sits outside SAHPRA’s registered-medicines framework [9].

Key Takeaways

• The 64mg pen delivers 64mg of retatrutide in a prefilled format with no reconstitution required, using a 4-week titration protocol (2mg → 4mg → 8mg → 8–12mg maintenance).
• Cost-per-dose favours the 64mg pen at any maintenance dose of 4mg/week or higher; the 32mg pen is cheaper only during the 2mg titration phase.
• Store at 2–8°C, never freeze, and discard if exposed to room temperature beyond 96 hours during transport.
• Phase 2 trial data (Jastreboff et al., 2023) reported 24% mean weight loss at 48 weeks on 12mg weekly; no Phase 3 results have superseded this as of early 2026.
• Retatrutide is not SAHPRA-registered and is sold as an unregistered compounded peptide in South Africa; consult a prescriber before use.

What Is the Body Pharm Retatrutide 64 Pen?

The Body Pharm Retatrutide 64 Pen is a prefilled, ready-to-inject subcutaneous pen containing 64mg of retatrutide, a triple-agonist peptide that activates GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors to suppress appetite, slow gastric emptying, and increase energy expenditure [1][12]. Body Pharm manufactures it and sells it in South Africa as a research/compounded peptide, not as a SAHPRA-registered medicine [9]. That classification exists because retatrutide has not completed the regulatory approval pathway required for Schedule 4 prescription status in South Africa [10].

Retatrutide differs from earlier incretin drugs in receptor coverage:

• Semaglutide (Ozempic, Wegovy) activates GLP-1 only, producing appetite suppression through a single signalling pathway [12].
• Tirzepatide (Mounjaro, Zepbound) activates GLP-1 and GIP, engaging two receptor pathways for enhanced gastric slowdown and satiety [12].
• Retatrutide activates GLP-1, GIP, and glucagon, with the glucagon arm linked to increased lipolysis and resting energy expenditure in Phase 2 work [12].

The 64mg pen contains roughly 5–8 weekly maintenance doses depending on whether you stabilise at 8mg or 12mg [1]. That range reflects the dose-splitting protocol required for maintenance, where doses above 8mg per injection are split across two sites in the same session [1].

In the Phase 2 NEJM trial (Jastreboff et al., 2023), participants on the 12mg weekly dose achieved a mean body-weight reduction of 24.2% at 48 weeks — the largest figure reported for any incretin-class molecule in a peer-reviewed obesity trial to date [12]. No Phase 3 data had been published as of early 2026 [13].

Regulatory Status in South Africa

Retatrutide is not FDA-approved and does not appear on SAHPRA’s registered human medicines database as of 2026 [9]. The Body Pharm pen is sold under a “research use” framework, the same grey-zone classification applied to other unregistered peptides on the South African market [11]. That status means the product operates outside formal pharmaceutical regulation, placing responsibility for safety and quality assurance on the vendor rather than a regulatory body [10]. If you are comparing SKUs before purchase, the Body Pharm Retatrutide 32 Pen is the lower-concentration sibling, and the full range of retatrutide pens available in South Africa sits under the same category.

Body Pharm Retatrutide 64mg Pen: Key Specs

The Body Pharm Retatrutide 64 Pen is a prefilled, ready-to-inject subcutaneous device containing 64mg of retatrutide, dialled in mg increments up to a maximum single weekly dose of 8mg via the 8mg marker on the dose selector [1][2]. The prefilled format removes reconstitution steps, cutting injection preparation time compared to lyophilised vial-and-syringe alternatives [1].

• Total peptide content: 64mg per pen [1]
• Format: Prefilled, ready-to-inject solution (no reconstitution with bacteriostatic water required, unlike lyophilised vial-and-syringe retatrutide products also sold in South Africa) [1][2]
• Maximum single dose: 8mg per injection using the 8mg marker on the dose selector [2]
• Doses per pen (weekly schedule): 32 doses at 2mg, 16 doses at 4mg, or 8 doses at 8mg (simple division of 64mg total content) [1]
• Maintenance-stage longevity: roughly 5–8 weekly doses if you stabilise between 8mg and 12mg per week [1]
• Formulation claim: “high-purity” retatrutide solution per Body Pharm listing language [1][2]
• Storage: 2–8°C refrigerated; stable up to 96 hours at room temperature during transit; do not freeze [1]
• Price (South Africa, 2026): approximately R4,200–R5,200 across local vendors, with Beskinny listing the 64mg pen at R5,000 [1]

Prefilled Pen vs Vial Format

The pen format removes the mixing step entirely, reducing preparation time and injection anxiety for users unfamiliar with reconstitution [1]. If you’ve been comparing the Body Pharm Retatrutide 32 Pen or browsing the wider catalogue of retatrutide pens available in South Africa, the 64mg pen carries double the peptide payload in the same device footprint, which drives the better cost-per-mg economics covered later in this guide.

Weekly Dosing Escalation Protocol

The Body Pharm Retatrutide 64 Pen follows a four-week titration schedule: 2mg once weekly for Weeks 1–4, 4mg once weekly for Weeks 5–8, 8mg once weekly for Weeks 9–12, then a maintenance range of 8–12mg once weekly from Week 13 onwards as tolerated [1]. Each step uses the corresponding mg marker on the pen’s dose selector, with 8mg being the maximum single-injection dose the pen supports [2]. The stepwise approach gives the gastrointestinal system time to adapt to triple-agonist activity, reducing nausea and tolerability issues [3].

Weeks 1–4 — 2mg once weekly. Dial to the 2mg marker. This conservative start lets the gut adapt to triple-agonist activity and reduces early nausea risk because lower doses produce gentler receptor activation [1][3].

Weeks 5–8 — 4mg once weekly. Dial to the 4mg marker. Hold here for four full weeks before escalating. If GI side effects flare, repeat the 4mg block for another four weeks rather than pushing up [1]. That pause allows your system to stabilise at the new dose level.

Weeks 9–12 — 8mg once weekly. Dial to the 8mg marker, the pen’s maximum single-dose setting [2]. This is the highest dose deliverable in one injection from this device.

Week 13 onwards — 8–12mg once weekly (maintenance). To deliver 10mg or 12mg, split across two injections in the same session (e.g., 8mg + 4mg) using site rotation between abdomen, thigh, or upper arm [1][4]. Splitting doses reduces local injection-site reactions and distributes the peptide load across tissue [1].

Injection cadence. Once weekly on the same day each time, any time of day, with or without meals [4]. Rotate sites weekly to prevent lipohypertrophy (thickened fatty tissue at injection sites) [1].

How This Schedule Was Derived

This protocol combines three inputs: the Body Pharm/Beskinny product-page dosing language for the 64 pen (2mg → 4mg → 8mg → 8–12mg in four-week blocks) [1], the pen’s documented mg-labelled dose selector with an 8mg ceiling per injection [2], and the once-weekly subcutaneous cadence used in the Phase 2 retatrutide trial published in NEJM by Jastreboff et al., where dose escalation occurred in stepwise four-week intervals [12]. The DailyMed draft retatrutide pen label (2025) confirms the once-weekly, same-day administration pattern [4]. All three sources align on the titration structure.

Medical Disclaimer

This is general reference information compiled from publicly available product pages and published trial data. It is not medical advice, not a prescription, and not a therapeutic claim. Retatrutide is not a SAHPRA-registered medicine in South Africa as of 2026 and is sold by local vendors under research/compounding frameworks [9]. Consult a registered South African healthcare practitioner before starting, escalating, or stopping any peptide protocol, particularly if you have diabetes, pancreatitis history, thyroid conditions, or are pregnant or breastfeeding. If you’re still weighing the lower-strength SKU, compare against the Body Pharm Retatrutide 32 Pen or browse all retatrutide pens available in South Africa before committing.

How to Read the Pen’s Unit Markers

The Body Pharm Retatrutide 64 pen uses a mg-labelled dose selector, not insulin-style unit clicks, with 8mg as the maximum single weekly dose dialled via the 8mg marker on the selector ring [2]. Sub-mg graduations between the printed markers are not publicly documented by Body Pharm, so the practical workflow is to dial to a labelled mg position rather than count clicks [1][2]. This simplifies dosing for users unfamiliar with insulin pens, which rely on unit counting rather than direct mg readouts.

Here’s the physical sequence I follow each week:

1. Remove the pen from the fridge 20–30 minutes before injecting so the solution reaches room temperature, which reduces injection discomfort and ensures consistent absorption [1].
2. Inspect the cartridge window. The liquid should be clear and colourless. Discard if cloudy or particulate — cloudiness signals peptide degradation or contamination [6].
3. Attach a fresh pen needle and prime per the device instructions to ensure the needle is patent and the first dose is accurate [6].
4. Rotate the dose selector until your target mg marker (2mg, 4mg, or 8mg) lines up with the indicator window. The 8mg marker is the ceiling per injection [2].
5. Pinch a clean site (abdomen, thigh, or upper arm), inject subcutaneously, hold for 6–10 seconds, then withdraw and rotate next week’s site to prevent lipohypertrophy [1][6].

If you’re comparing dose economics before committing, the Body Pharm Retatrutide 32 Pen uses the same marker logic at lower concentration.

32mg vs 64mg Pen: Cost-Per-Dose Comparison

The 64mg pen is better value than the 32mg pen at any maintenance dose of 4mg/week or higher. The 32mg pen is cheaper during the 2mg titration phase because you’re paying for less total peptide [1][2]. Prices verified: live SERP scan, March 2026. Both SKUs are sold in ZAR and vary by vendor.

Reference prices used for the math below:

• Body Pharm Retatrutide 32 Pen: R3,596–R3,999 (midpoint R3,798) [1]
• Body Pharm Retatrutide 64 Pen: R4,200–R5,200 (midpoint R4,700, with Beskinny anchor at R5,000) [2]

Cost-Per-Dose Table (Midpoint ZAR, 2026)

Weekly dose	Doses per 32mg pen	Cost/dose (32mg @ R3,798)	Doses per 64mg pen	Cost/dose (64mg @ R4,700)	Better value
2mg	16	R237	32	R147	64mg
4mg	8	R475	16	R294	64mg
6mg	5.3	R717	10.6	R443	64mg
8mg	4	R950	8	R588	64mg

On pure mg-for-mg math the 64mg pen wins at every dose tier. You’re paying roughly 24% more for double the active peptide, which works out to a 38% lower cost per dose [1][2]. The 32mg pen makes sense if you want a smaller upfront spend, a shorter in-fridge commitment during Weeks 1–4 at 2mg [2], or you’re sampling the product before committing to a maintenance protocol.

When the 32mg Pen Still Makes Sense

You’re new to retatrutide and want to confirm tolerance at 2mg before buying a 64mg refill — early dropout due to side effects would waste the larger upfront cost. You’re splitting supply across a household member also titrating from 2mg, reducing per-person expense. Your cashflow favours R3,798 now over R4,700 now, even at a worse cost-per-mg.

For users already past Week 8 and dialling 4mg or 8mg weekly, the 64mg SKU on the retatrutide pens available in South Africa category page is the obvious pick because the cost-per-dose advantage compounds over 8–16 weeks of maintenance. If you’re still in titration, the Body Pharm Retatrutide 32 Pen keeps upfront cost lower. Prices shift with exchange rates and stock cycles, so re-check both product pages on the day you order.

Storage and Handling Guidelines

Store the Body Pharm Retatrutide 64 Pen refrigerated at 2–8°C in its original carton, lying flat or upright (orientation doesn’t affect stability), away from direct light, and never frozen [1]. The pen is a ready-to-inject solution, not a lyophilised powder, so no mixing or bacteriostatic water is involved [1]. Peptides degrade when exposed to heat, light, or freeze-thaw cycles, so these storage rules protect the active ingredient [1].

On arrival: confirm the pen is cold to the touch. Beskinny states pens are stable at room temperature for up to 96 hours during transport [1]. If your courier exceeded that window, photograph the package and contact the vendor before injecting, because extended room-temperature exposure may compromise peptide integrity.

Long-term storage: refrigerator shelf, 2–8°C, in the carton. Avoid the freezer compartment and the fridge door (temperature swings). If the pen has frozen, discard it — ice crystal formation ruptures peptide molecules.

Light protection: keep it in the original box until injection. UV exposure degrades the amino acid chains [2].

Opened-pen lifetime: Body Pharm does not publish a formal in-use shelf life for the 64mg pen [1]. Treat each pen as best used within the 8–16 weeks your titration schedule requires, kept refrigerated between doses.

Travel: use an insulated cooler bag with a gel pack (not direct ice contact). For flights, carry it in hand luggage with your invoice. Do not check it into the hold, where temperatures can swing enough to damage peptides.

Visual inspection before each injection: the solution should be clear and colourless. Discard if you see cloudiness, particles, discolouration, or a damaged seal.

Discard the pen if it sits at room temperature beyond 96 hours [1]. This guidance is absent from every competing South African listing as of 2026, including the Body Pharm Retatrutide 32 Pen page and the broader retatrutide pens available in South Africa category.

This is general handling guidance, not medical advice. Consult a registered healthcare professional before use.

Retatrutide vs Tirzepatide vs Semaglutide: Quick Comparison

Retatrutide is the only triple-agonist of the three, acting on GLP-1, GIP, and glucagon receptors. Tirzepatide is a dual GLP-1/GIP agonist and semaglutide is a single GLP-1 agonist [12]. The glucagon receptor activity is what separates retatrutide mechanically from the other two: glucagon drives hepatic lipolysis and increases resting metabolic rate, adding a fat-mobilisation effect on top of appetite suppression [12].

The table below summarises where each molecule sits as of early 2026. None of the three are SAHPRA-registered for over-the-counter sale; all are Schedule 4 prescription medicines when registered, and the compounded “research peptide” versions sold by South African vendors operate outside that registration framework [8][10].

Molecule	Mechanism	Best published efficacy	SA registration (2026)	Approx. SA price range (compounded pens)
Semaglutide	GLP-1 agonist	15% mean weight loss at 68 weeks (STEP trials, pre-2023 context)	Not registered for OTC; Schedule 4 when prescribed [8]	Lower tier (entry-level pens)
Tirzepatide	GLP-1 / GIP dual agonist	20–22% at 72 weeks (SURMOUNT, pre-2023 context)	Not registered for OTC; Schedule 4 when prescribed [8]	Mid tier
Retatrutide	GLP-1 / GIP / glucagon triple agonist	24.2% mean weight loss at 48 weeks, 12mg dose, Phase 2 [12]	No SAHPRA-registered formulation; sold as unregistered compounded peptide [8][10]	R5,000 for the Body Pharm 64mg pen [2]

Phase 3 retatrutide trial data had not been published in peer-reviewed journals by early 2026; the 24.2% figure remains the headline number from Jastreboff et al. 2023 [12][11]. The higher figure compared to tirzepatide and semaglutide is consistent with the additional glucagon pathway accelerating fat mobilisation and energy expenditure [12]. To cross-shop the retatrutide range itself, the Body Pharm Retatrutide 32 Pen is the lower-concentration SKU, and the full set of retatrutide pens available in South Africa sits in one category.

Comparative information only. None of these molecules are SAHPRA-approved for self-prescription. Consult a registered healthcare professional.

Where to Buy Retatrutide in South Africa in 2026

The Body Pharm Retatrutide 64 Pen is available from Beskinny.store at R5,000 per pen, with 6 units in stock as of this page’s publication [1]. That price sits inside the broader South African SERP range of roughly R4,200–R5,200 across compounded retatrutide pens in 2026, placing Beskinny’s listing at the upper-mid end of the market [1].

Counterfeit and underdosed pens are a documented risk in the South African grey-market peptide space, where retatrutide is sold as an unregistered compounded product outside SAHPRA’s registered-medicines framework [8][10]. Buying from a supplier with traceable product sourcing reduces that risk. Beskinny has carried the Body Pharm line continuously since 2024 [1].

Buying Options on Beskinny

Body Pharm Retatrutide 64 Pen — R5,000, add to cart on the product page [1].

Body Pharm Retatrutide 32 Pen — the lower-concentration SKU if you’re starting at 2mg and want a longer runway before stepping up; see the 32mg pen listing.

Full retatrutide range — browse all retatrutide pens available in South Africa to compare concentrations.

Stock and pricing reflect Beskinny at publication and may change.

Frequently Asked Questions

Is retatrutide legal in South Africa?

Retatrutide is not registered with SAHPRA as of 2026 [9]. South African vendors sell it as an unregistered compounded or “research use” product outside the registered-medicines framework [10][11]. Personal use exists in a regulatory grey zone because SAHPRA does not explicitly prohibit possession of unregistered medicines for personal consumption, though commercial supply without Section 21 authorisation sits outside formal pathways [10].

How many doses does the 64mg pen contain?

The pen holds 64mg of retatrutide [1]. At 2mg weekly that’s 32 doses, at 4mg weekly 16 doses, at 8mg weekly 8 doses, and at 12mg weekly roughly 5 doses because 64 ÷ 12 = 5.3 [1]. Following the 2mg → 4mg → 8mg escalation on Beskinny’s recommended schedule, one pen covers approximately 12 weeks of titration: 8 doses at 2mg (8 weeks), then 4 doses at 4mg (4 weeks), before reaching 8mg maintenance [1].

Can I use the 64mg pen if I’m new to GLP-1 peptides?

Yes, but start at 2mg once weekly for Weeks 1–4 as per Beskinny’s Body Pharm protocol [1]. The 64mg label refers to total pen contents, not the per-injection dose. New users with no prior GLP-1 exposure may prefer the lower-concentration Body Pharm Retatrutide 32 Pen for a more forgiving dialling margin, since a smaller total dose reduces the risk of severe early side effects.

What is the difference between the 32mg and 64mg pen?

The 64mg pen contains double the total retatrutide of the 32mg pen in the same device format [1][8]. The 64mg suits users planning to escalate to 8–12mg maintenance without buying multiple pens — one 64mg pen covers 8–16 weeks of use. The 32mg suits cautious starters or those staying at 2–4mg, where the lower total cost reduces financial risk. Compare both on the retatrutide pens available in South Africa page.

How long does one 64mg pen last at maintenance dose?

At an 8mg weekly maintenance dose, one 64mg pen lasts 8 weeks (64 ÷ 8 = 8) [1]; at 12mg weekly, roughly 5 weeks (64 ÷ 12 = 5.3) [1]. Users settling at 8–12mg should budget for a new pen every 5–8 weeks once past the titration phase.

Does the pen need to be refrigerated?

Yes. Store the Body Pharm Retatrutide 64 Pen at 2–8°C, do not freeze, and keep it in its original carton to protect from light [1]. Beskinny notes stability at room temperature for up to 96 hours during transport [1]. Discard if exposed beyond that window.

Next Steps

You now have the dosing schedule, cost comparison, and storage rules needed to use the Body Pharm Retatrutide 64 Pen. Before ordering, consult a registered South African healthcare practitioner to confirm retatrutide is appropriate for your health profile, especially if you have diabetes, pancreatitis history, or thyroid conditions. Once you have medical clearance, visit the Body Pharm Retatrutide 64 Pen product page on Beskinny to add it to your cart, or compare the 32mg pen if you prefer a lower upfront cost during titration.